此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

针对已完成先前贝那利珠单抗(Fasenra)临床研究并可从继续治疗中获益的参与者的延展研究 (ROSY-F)

2026年11月12日 更新者:AstraZeneca

ROSY-F:针对已完成先前贝那利珠单抗(Fasenra)研究、且经研究者判断可从继续治疗中临床获益的受试者开展的延续研究

The rationale of the roll-over study (ROSY) is to provide continuous access to study treatment for participants who have completed or exited a parent study and are deemed appropriate for continued benralizumab treatment, as judged by the Investigator, while monitoring long-term safety and tolerability of benralizumab.

研究概览

详细说明

This will be an open-label, non-randomised, multicentre, international study for eligible participants who have completed or exited a parent study and are deemed appropriate for continued benralizumab treatment as judged by the Investigator. Any clinical study conducted with benralizumab (Fasenra) for indications such as asthma, EGPA, HES and future indications from additional parent studies, is potentially a parent study.

Each participant continuing to receive clinical benefit from benralizumab but with no access to the drug after exiting the parent study must be seen at the Investigator site, offered the opportunity to transition to the ROSY-F. The duration of clinical benefit from study treatment for an individual participant can exceed the duration of a clinical trial. To ensure continued supply of treatment to a participant who, as judged by the Investigator, is still receiving benefit when he/she either completes or exits the parent study or when the parent study closes, a roll-over study is the most universally acceptable mechanism for continuing to provide ongoing study treatment.

研究类型

介入性

注册 (估计的)

230

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Haifa、以色列、34362
        • 招聘中
        • Research Site
      • Holon、以色列、5822012
        • 招聘中
        • Research Site
      • Petah Tikva、以色列、492025
        • 尚未招聘
        • Research Site
    • Alberta
      • Calgary、Alberta、加拿大、T2N 4N1
        • 尚未招聘
        • Research Site
    • Ontario
      • Hamilton、Ontario、加拿大、L8N 4A6
        • 招聘中
        • Research Site
      • Toronto、Ontario、加拿大、M5G 1E2
        • 招聘中
        • Research Site
      • Toronto、Ontario、加拿大、M5G 1X8
        • 尚未招聘
        • Research Site
      • Toronto、Ontario、加拿大、M5T 3A9
        • 招聘中
        • Research Site
      • Ahmedabad、印度、380052
        • 撤销
        • Research Site
      • Ajmer、印度、305001
        • 尚未招聘
        • Research Site
      • Istanbul、土耳其(türkiye)、34093
        • 尚未招聘
        • Research Site
      • Innsbruck、奥地利、6020
        • 尚未招聘
        • Research Site
      • Roma、意大利、00165
        • 撤销
        • Research Site
      • Brussels、比利时、1070
        • 招聘中
        • Research Site
      • Edegem、比利时、B-2650
        • 尚未招聘
        • Research Site
      • Bron、法国、69677
        • 尚未招聘
        • Research Site
      • Marseille、法国、13915
        • 招聘中
        • Research Site
      • Montpellier、法国、34090
        • 招聘中
        • Research Site
      • Nantes、法国、44093
        • 招聘中
        • Research Site
      • Paris、法国、75014
        • 招聘中
        • Research Site
      • Paris、法国、75018
        • 招聘中
        • Research Site
      • Pessac、法国、33604
        • 招聘中
        • Research Site
      • Suresnes、法国、92151
        • 招聘中
        • Research Site
      • Chęciny、波兰、26-060
        • 尚未招聘
        • Research Site
      • Gdansk、波兰、80-214
        • 尚未招聘
        • Research Site
      • Lodz、波兰、90-302
        • 撤销
        • Research Site
      • Lodz、波兰、90-153
        • 尚未招聘
        • Research Site
    • Colorado
      • Aurora、Colorado、美国、80045
        • 尚未招聘
        • Research Site
    • Maryland
      • Bethesda、Maryland、美国、20892
        • 尚未招聘
        • Research Site
    • Michigan
      • Ann Arbor、Michigan、美国、48105
        • 尚未招聘
        • Research Site
    • New Jersey
      • Northfield、New Jersey、美国、08225
        • 尚未招聘
        • Research Site
    • New York
      • The Bronx、New York、美国、10459
        • 尚未招聘
        • Research Site
    • North Carolina
      • Durham、North Carolina、美国、27705
        • 尚未招聘
        • Research Site
    • Ohio
      • Cleveland、Ohio、美国、44106
        • 招聘中
        • Research Site
    • Utah
      • Salt Lake City、Utah、美国、84107
        • 尚未招聘
        • Research Site
      • London、英国、W2 1NY
        • 招聘中
        • Research Site
      • Rotterdam、荷兰、3015 GD
        • 尚未招聘
        • Research Site
      • Buenos Aires、阿根廷、C1121ABE
        • 招聘中
        • Research Site
      • Florida、阿根廷、B1602DQD
        • 招聘中
        • Research Site
      • Lobos、阿根廷、7240
        • 尚未招聘
        • Research Site
      • Mar del Plata、阿根廷、B7600FYK
        • 招聘中
        • Research Site
      • Mendoza、阿根廷、5500
        • 招聘中
        • Research Site
      • Mendoza、阿根廷、M5500
        • 招聘中
        • Research Site
      • Rosario、阿根廷、2000
        • 招聘中
        • Research Site
      • San Juan Bautista、阿根廷、1888
        • 尚未招聘
        • Research Site
      • Incheon、韩国、400-711
        • 招聘中
        • Research Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

6年 及以上 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • 1. Provision of signed and dated written ICF.

    2. Participants completing minimum required OLE period of a parent study and judged by the Investigator to benefit from continued treatment.

  • 3. Participants must agree to follow the contraception requirements as per their respective parent protocols from study inclusion up to 12 weeks after the last dose of study treatment.

  • 4. Participants without childbearing potential at enrolment must agree to start appropriate contraception if childbearing potential develops during the study and up to 12 weeks after the last dose of study treatment.

  • 5. Participants who are unable to access commercially available benralizumab and clinically indicated for continuation.

Exclusion Criteria:

  • 1. Ongoing, unresolved AE requiring interruption of treatment at the end of the prior parent study (ie, when the parent study is either completed or closed) that in the Investigator's opinion would prevent restarting benralizumab.
  • 2. Participants who are planning to use live/live-attenuated vaccines.
  • 3. Participants who are planning to use biologic therapies, including B-cell therapies with the exception for the treatment of co-morbidities where no alternative medicine is available.
  • 4. Participants with any medical condition (such as cancer or viral infections [hepatitis]) or psychiatric condition that, in the opinion of the Investigator, could jeopardise or would compromise the participant's ability to participate in this study as determined by the Investigator based on protocol required assessments.
  • 5. Concurrently enrolled in any clinical study (other than a parent study).
  • 6. Participants who discontinued the parent study prior to completing the minimum OLE or treatment period.
  • 7. Local access to commercially available benralizumab.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Benralizumab arm

Benralizumab will be administrated as an subcutaneous injection at a frequency in line with that received in the parent study.

Accessorized Pre-Filled Syringe (Solution for injection).

其他名称:
  • 法森拉

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Safety will be evaluated by monitoring and assessing SAEs and non-serious AEs reported throughout the study and until 8 weeks after the last dose of benralizumab
大体时间:From baseline until 8 weeks after the last dose of benralizumab

To provide benralizumab to participants who continue to benefit at the end of the parent clinical study while monitoring long-term safety and tolerability of benralizumab

From baseline until 8 weeks after the last dose of benralizumab

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年7月24日

初级完成 (估计的)

2029年12月27日

研究完成 (估计的)

2029年12月27日

研究注册日期

首次提交

2026年2月17日

首先提交符合 QC 标准的

2026年2月27日

首次发布 (实际的)

2026年3月3日

研究记录更新

最后更新发布 (实际的)

2026年11月13日

上次提交的符合 QC 标准的更新

2026年11月12日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

IPD 共享时间框架

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD 共享访问标准

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org.

Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

IPD 共享支持信息类型

  • 研究方案
  • 树液

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅